Managers / Q3 2023 · view latest →
Aviva Holdings Ltd.
CIK 0001603935 · ALBANY FINANCIAL CENTER, SUITE 207, LEWIS DRIVE N7776, NEW PROVIDENCE, C5, 00000 · 407-909-9970
Reported Value
Under review
reported total failed a data-quality check
Positions
5
Filings on Record
28
2019–present window
Filed
Nov 14, 2023
original filing
Summary
The book was largely unchanged from Q2 2023.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Common Stock · 93.6% · $146M
- US DOMESTIC · 6.4% · $10M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| MRTXEURMIRATI THERAPEUTICS INC | HELD | +0 | 3.14M | +$136M | $137M |
| INSEEGO CORP | HELD | +0 | 24.46M | +$10M | $10M |
| INSGEURINSEEGO CORP | HELD | +0 | 20.65M | +$9M | $9M |
| TNGXTango Therapeutics Inc. | HELD | +0 | 27.0K | +$303,491 | $303,581 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2023
3 positions
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | MRTXEURMIRATI THERAPEUTICS INChistory → | COMMON | 87.83% | $137M | 3.14M |
| 2 | INSGEURINSEEGO CORP | Note 3.250%5/0 · COMMON | 11.98% | $19M | 45.10M |
| 3 | TNGXTango Therapeutics Inc. | Common | 0.20% | $303,581 | 27.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q4 2024 | $21M | 1 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $41M | 2 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $26M | 2 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $13M | 2 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $13M | 2 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | Under review | 5 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | Under review | 5 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $143M | 5 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $174M | 5 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $277M | 6 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $278M | 7 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $379M | 7 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $615M | 7 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $709M | 7 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $724M | 6 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $752M | 4 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $1.0B | 4 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $767M | 4 | Nov 17, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2020 | $643M | 6 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $439M | 5 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019REVEALED | $669M | 6 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $370M | 6 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $478M | 6 | Aug 28, 2019 | RESTATEMENT | changes · EDGAR ↗ |
| Q1 2019 | $456M | 9 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $317M | 10 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 2 additional managers.
- Braslyn Ltd.028-17341
- Shelton Ventures Inc.028-17344
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.